As a pioneer in the field of anesthesia, Organon has been providing innovative products for more than 40 years. We hold leading positions in muscle relaxants and objective neuromuscular monitoring and continue to develop products which optimize patient safety and care, as well as therapeutic cost-effectiveness.

For general anesthesia, anesthesiology professionals administer three main groups of anesthetic agents: hypnotics, analgesics and muscle relaxants.

Hypnotic agents, also known as induction agents, render the patient unconscious. Years ago, large doses of hypnotics were necessary to achieve the deep level of sleep and muscle relaxation required for painless surgery. Today, however, smaller doses are used to keep the patient unconscious as other more efficient drugs have been developed to relieve pain and relax the muscles. This helps to ensure a more rapid recovery.

Analgesics are used to reduce pain during and after surgery, and are necessary both for the patient’s comfort and safety.

Many patients also receive a muscle relaxant to induce complete muscle paralysis. This is particularly important when it is necessary to keep patients still during major or delicate surgery, or to allow bone and muscle manipulation, for example during orthopedic surgery. Patients given muscle relaxants can no longer breathe unassisted and must be artificially ventilated.

Organon leadership
Today, our products are the number one choice for many anesthesiology professionals around the world. Organon recognizes the achievements of these professionals, the importance and complexity of the work they do and remains committed to continuing to meet their needs through development of innovative solutions that assist them in caring for their patients.

In the more than 40 years of anesthesia research and development together with anesthesiology professionals, Organon has introduced several innovative products into clinical practice such as Pavulon®, Norcuron®, Esmeron®, TOF-Watch® and Orgaran®.

Organon is currently the only company with major investments in muscle relaxant innovations and we will continue to innovate within anesthesia through our research and development program by working in close cooperation with anesthesiology professionals. The Organon efforts in anesthesia are currently focussed on the reversal of muscle relaxants and the treatment of pain.